Literature DB >> 26305823

The APOBEC3B deletion polymorphism is associated with prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and Toxoplasma gondii co-infection among HIV-infected individuals.

Afiono Agung Prasetyo1, Ratna Sariyatun2, Yulia Sari3, Sri Haryati3, Zainal Arifin Adnan4, Seiji Kageyama5.   

Abstract

BACKGROUND: Data regarding the influence of the APOBEC3B deletion on infectious diseases remain limited and shown discrepancies.
OBJECTIVES: To characterize the APOBEC3B deletion polymorphism status and its association with prevalence of co-infection with blood-borne pathogens in Indonesian HIV-infected individuals.
MATERIALS AND METHODS: A total of 597 HIV-positive blood samples were tested for the hepatitis B virus (HBV), hepatitis C virus (HCV), Torque Teno virus (TTV), GB virus-C (GBV-C), and Toxoplasma gondii. Nucleic acid was extracted from plasma samples and used for the molecular detection of HIV RNA, HBV DNA, HCV RNA, TTV DNA, and GBV-C RNA, whereas HBsAg, anti-HCV, IgM and IgG anti-T. gondii were detected through serological testing. The APOBEC3B deletion polymorphism was genotyped by polymerase chain reaction (PCR).
RESULTS: The deletion genotype was associated with HCV viremia (p<0.001) as well as elevated IgG anti-T. gondii (adjusted OR [aOR]=3.4). The deletion genotype was also associated with decreased levels of HBsAg (aOR=0.03), and anti-HCV (aOR=0.1). D/D was frequently found in HIV-infected individuals with CD4+T cells<14% (aOR=5.8). The intact genotype was associated with a reduced likelihood of a CD4+T cell count<200 cells/μL (aOR=0.2) but a higher prevalence of TTV co-infection (aOR=8.6).
CONCLUSIONS: The APOBEC3B deletion polymorphism was found to be associated with HBV, HCV, TTV, and T. gondii co-infection in Indonesian HIV-infected individuals.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APOBEC; HBV; HCV; HIV; TTV; Toxoplasma gondii

Mesh:

Substances:

Year:  2015        PMID: 26305823     DOI: 10.1016/j.jcv.2015.07.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

Review 1.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.

Authors:  Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

2.  APOBEC3B lysine residues are dispensable for DNA cytosine deamination, HIV-1 restriction, and nuclear localization.

Authors:  Amy M Molan; Heather M Hanson; Cynthia M Chweya; Brett D Anderson; Gabriel J Starrett; Christopher M Richards; Reuben S Harris
Journal:  Virology       Date:  2017-08-23       Impact factor: 3.616

Review 3.  APOBEC: A molecular driver in cervical cancer pathogenesis.

Authors:  Sundaramoorthy Revathidevi; Avaniyapuram Kannan Murugan; Hirofumi Nakaoka; Ituro Inoue; Arasambattu Kannan Munirajan
Journal:  Cancer Lett       Date:  2020-10-07       Impact factor: 8.679

4.  Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia.

Authors:  Ping An; Sudhir Penugonda; Christian W Thorball; Istvan Bartha; James J Goedert; Sharyne Donfield; Susan Buchbinder; Elizabeth Binns-Roemer; Gregory D Kirk; Wenyan Zhang; Jacques Fellay; Xiao-Fang Yu; Cheryl A Winkler
Journal:  PLoS Genet       Date:  2016-03-04       Impact factor: 5.917

5.  The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population.

Authors:  Katarzyna Klonowska; Wojciech Kluzniak; Bogna Rusak; Anna Jakubowska; Magdalena Ratajska; Natalia Krawczynska; Danuta Vasilevska; Karol Czubak; Marzena Wojciechowska; Cezary Cybulski; Jan Lubinski; Piotr Kozlowski
Journal:  Oncotarget       Date:  2017-07-19

Review 6.  Human APOBEC3 Variations and Viral Infection.

Authors:  Shiva Sadeghpour; Saeideh Khodaee; Mostafa Rahnama; Hamzeh Rahimi; Diako Ebrahimi
Journal:  Viruses       Date:  2021-07-14       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.